Clinical Trial Detail

NCT ID NCT02761694
Title ARQ 751 as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors ArQule
Indications

Advanced Solid Tumor

Her2-receptor negative breast cancer

triple-receptor negative breast cancer

Therapies

ARQ 751 + Paclitaxel

ARQ 751

ARQ 751 + Fulvestrant

Age Groups: adult senior

Additional content available in CKB BOOST